|
8 Companies |
|
2 Products |
|
2 Products |
|
6 Mechanisms of Action |
|
0 Trials |
|
25 News |
|
- | Trial completion: CULPRIT-SHOCK: Culprit Lesion Only PCI Versus Multivessel PCI in Cardiogenic Shock (clinicaltrials.gov) - Nov 9, 2017
P4, N=706, Completed, Sponsor: University of Luebeck
Recruiting --> Completed
- | Trial completion: IABP-SHOCK II: Intraaortic Balloon Pump in Cardiogenic Shock II (clinicaltrials.gov) - May 2, 2017
P4, N=600, Completed, Sponsor: University of Leipzig
Recruiting --> Completed Active, not recruiting --> Completed
- | Trial completion: SHOCK-COOL: Mild Hypothermia in Cardiogenic Shock Complicating Myocardial Infarction (clinicaltrials.gov) - May 2, 2017
P=N/A, N=40, Completed, Sponsor: University of Leipzig
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | epinephrine / Generic mfg.
Trial completion, Enrollment change, Trial primary completion date: OptimaCCt: Study Comparing the Efficacy and Tolerability of Epinephrine and Norepinephrine in Cardiogenic Shock (clinicaltrials.gov) - Apr 20, 2017
P4, N=58, Completed, Sponsor: Central Hospital, Nancy, France
Active, not recruiting --> Completed Recruiting --> Completed | N=80 --> 58 | Trial primary completion date: Sep 2016 --> Feb 2016
- Trial primary completion date: CULPRIT-SHOCK: Culprit Lesion Only PCI Versus Multivessel PCI in Cardiogenic Shock (clinicaltrials.gov) - Oct 11, 2016
P4, N=706, Recruiting, Sponsor: University of Luebeck
Recruiting --> Completed | N=80 --> 58 | Trial primary completion date: Sep 2016 --> Feb 2016 Trial primary completion date: Dec 2016 --> Sep 2017
- Enrollment closed: IABP-SHOCK II: Intraaortic Balloon Pump in Cardiogenic Shock II (clinicaltrials.gov) - Apr 28, 2016
P4, N=600, Active, not recruiting, Sponsor: University of Leipzig
Trial primary completion date: Dec 2016 --> Sep 2017 Completed --> Active, not recruiting
- cyclosporin A microemulsion / Generic mfg.
Enrollment change, Trial withdrawal: CLOTILDE: Cyclosporine in Acute Myocardial Infarction Complicated by Cardiogenic Shock (clinicaltrials.gov) - Mar 17, 2016
P2, N=0, Withdrawn, Sponsor: Hospices Civils de Lyon
Completed --> Active, not recruiting N=100 --> 0 | Not yet recruiting --> Withdrawn
- | Trial completion: Shock Trial: Should We Emergently Revascularize Occluded Coronaries for Cardiogenic Shock. (clinicaltrials.gov) - Feb 27, 2016
P3, N=0, Completed, Sponsor: New England Research Institutes
N=100 --> 0 | Not yet recruiting --> Withdrawn No longer recruiting --> Completed
- Trial primary completion date: CULPRIT-SHOCK: Culprit Lesion Only PCI Versus Multivessel PCI in Cardiogenic Shock (clinicaltrials.gov) - Dec 5, 2015
P4, N=706, Recruiting, Sponsor: University of Luebeck
No longer recruiting --> Completed Trial primary completion date: Aug 2016 --> Dec 2016
- Enrollment closed, Trial primary completion date: SHOCK-COOL: Mild Hypothermia in Cardiogenic Shock Complicating Myocardial Infarction (clinicaltrials.gov) - Nov 15, 2015
P=N/A, N=40, Active, not recruiting, Sponsor: University of Leipzig
Trial primary completion date: Aug 2016 --> Dec 2016 Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2014 --> Nov 2015
- cyclosporin A microemulsion / Generic mfg.
Trial initiation date: CLOTILDE: Cyclosporine in Acute Myocardial Infarction Complicated by Cardiogenic Shock (clinicaltrials.gov) - Sep 22, 2015
P2, N=100, Not yet recruiting, Sponsor: Hospices Civils de Lyon
Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2014 --> Nov 2015 Initiation date: Sep 2014 --> Sep 2015
- ampreloxetine (TD-9855) / Theravance Biopharma
Phase classification: Levosimendan in Acute Heart Failure Following Acute Myocardial Infarction. (clinicaltrials.gov) - May 13, 2015
P1, N=6, Completed, Sponsor: Theravance Biopharma R & D, Inc.
Initiation date: Sep 2014 --> Sep 2015 Phase classification: P4 --> P1
- cyclosporin A microemulsion / Generic mfg.
Phase classification: CLOTILDE: Cyclosporine in Acute Myocardial Infarction Complicated by Cardiogenic Shock (clinicaltrials.gov) - Aug 15, 2014
P2, N=100, Not yet recruiting, Sponsor: Hospices Civils de Lyon
Phase classification: P4 --> P1 Phase classification: P3 --> P2
- epinephrine / Generic mfg.
Trial primary completion date: OptimaCCt: Study Comparing the Efficacy and Tolerability of Epinephrine and Norepinephrine in Cardiogenic Shock (clinicaltrials.gov) - Jun 26, 2014
P4, N=80, Recruiting, Sponsor: Central Hospital, Nancy, France
Phase classification: P3 --> P2 Trial primary completion date: Jul 2014 --> Sep 2016
- cyclosporin A microemulsion / Generic mfg.
Trial primary completion date: CLOTILDE: Cyclosporine in Acute Myocardial Infarction Complicated by Cardiogenic Shock (clinicaltrials.gov) - May 27, 2014
P3, N=100, Not yet recruiting, Sponsor: Hospices Civils de Lyon
Trial primary completion date: Jul 2014 --> Sep 2016 Trial primary completion date: Jan 2016 --> Oct 2015
- cyclosporin A microemulsion / Generic mfg.
Trial completion date: CLOTILDE: Cyclosporine in Acute Myocardial Infarction Complicated by Cardiogenic Shock (clinicaltrials.gov) - May 27, 2014
P3, N=100, Not yet recruiting, Sponsor: Hospices Civils de Lyon
Trial primary completion date: Jan 2016 --> Oct 2015 Trial completion date: Jan 2016 --> Oct 2015
- | cyclosporin A microemulsion / Generic mfg.
Trial initiation date: CLOTILDE: Cyclosporine in Acute Myocardial Infarction Complicated by Cardiogenic Shock (clinicaltrials.gov) - May 27, 2014
P3, N=100, Not yet recruiting, Sponsor: Hospices Civils de Lyon
Trial completion date: Jan 2016 --> Oct 2015 Initiation date: Sep 2013 --> Jan 2014
- Trial completion: Australia and New Zealand Adult Extracorporeal Membrane Oxygenation (ECMO) Audit 2005 (clinicaltrials.gov) - Mar 5, 2014
P=N/A, N=0, Completed, Sponsor: Bayside Health
Initiation date: Sep 2013 --> Jan 2014 Recruiting --> Completed
- Biomarker, Trial completion: CardShock Study and Registry (clinicaltrials.gov) - Jan 1, 2014
P=N/A, N=220, Completed, Sponsor: Helsinki University Central Hospital
Recruiting --> Completed Active, not recruiting --> Completed
- ampreloxetine (TD-9855) / Theravance Biopharma
Trial completion: Levosimendan in Acute Heart Failure Following Acute Myocardial Infarction. (clinicaltrials.gov) - Nov 10, 2013
P4, N=61, Completed, Sponsor: Oslo University Hospital
Active, not recruiting --> Completed Not yet recruiting --> Completed
- | New P4 trial: CULPRIT-SHOCK: Culprit Lesion Only PCI Versus Multivessel PCI in Cardiogenic Shock (clinicaltrials.gov) - Aug 20, 2013
P4, N=706, Recruiting, Sponsor: University of Luebeck
- | ampreloxetine (TD-9855) / Theravance Biopharma
New P4 trial: Levosimendan in Acute Heart Failure Following Acute Myocardial Infarction. (clinicaltrials.gov) - Aug 14, 2013
P4, N=61, Completed, Sponsor: Oslo University Hospital
- || cyclosporin A microemulsion / Generic mfg.
New P3 trial: CLOTILDE: Cyclosporine in Acute Myocardial Infarction Complicated by Cardiogenic Shock (clinicaltrials.gov) - Jul 15, 2013
P3, N=100, Not yet recruiting, Sponsor: Hospices Civils de Lyon
- Trial completion: IABP-SHOCK II: Intraaortic Balloon Pump in Cardiogenic Shock II (clinicaltrials.gov) - Jun 16, 2013
P4, N=600, Completed, Sponsor: University of Leipzig
Not yet recruiting --> Completed Recruiting --> Completed
- Enrollment change: HEROIC (Heparin Requirement in Counterpulsation) (clinicaltrials.gov) - Sep 21, 2012
P2, N=46, Completed, Sponsor: Justin Trivax
Recruiting --> Completed N=276 --> 46